BioPharma Today

BIOASIA 2012: The widest global platform for optimizing bio-business, partnerships and opportunities in Biotechnology

Under the overarching theme of “Optimizing Opportunities”, the ninth session of the most awaited global forum on Biotechnology - BioAsia 2012 – is, this year, geared to be bigger, wider and experientially more dynamic a platform than ever before. Of course, it will certainly be both the business-face and the knowledge repository of the Biotech world, bringing together key industry stakeholders across categories.

China: The New Land of Opportunity for Biopharma Companies?

The pharmaceutical and life sciences landscape is changing fast in China. There are close to 1,000 bio-related companies in China, and half were established in the last five years or so. Citi expects China’s pharmaceutical market to grow from its current level of $40 billion to $100 billion by 2015 and to $200 billion by 2020, which will make it the second largest in the world, passing Japan along the way.

Pharmaceuticals and Biosimilars in Korea: Challenges and Opportunities - Straight From The Source

By 2015, the Korean biosimilar market is expected to have a market share of 6.9% in the global pharmaceutical market. If your organization is aiming to enter this burgeoning arena, this future-focused, 90-minute webinar, sponsored by PharmAsia News, is a must-see event.

India Moves To Close Traditional Medicine Colleges Not Operating According To Standards

Article preview from "PharmAsia News"-  August 30, 2011

NEW DELHI - As part of a comprehensive overhaul, India's Department of Ayush, which deals with the Indian traditional system of medicine, locally known as ayurveda, has decided to close 180 ayurveda-based medical colleges that have not been operating according to prescribed standards.

How's Your Guanxi?

You may have heard of the Chinese business concept of guanxi, but do you really understand it? The term, loosely defined as "relationship," can be maligned in the West, but there's more to it than cronyism.

Fidelity Growth Partner Asia's Norman Chen On Being An Active Investor In China: An Interview With PharmAsia News (Part 1 of 2)

Fidelity Growth Partners Asia has made its name on several blockbuster investments in China. In the IT sector, Fidelity invested in Alibaba, China's leading e-commerce company. In healthcare, Fidelity was an early investor in China's leading CRO WuXi AppTec Inc. and remains one of its largest shareholders.

 

Are you interested in China Healthcare Investment?

The Industry's most influential Chinese and global thought leaders will gather to promote the development of the Chinese healthcare market.

A Race for Growth: Leveraging Cross Border Opportunities

UCLA's Anderson School of Management, will host the Wilbur K. Woo Greater China Business Conference on March 4, 2011.

China One Step Closer To Global Standards For Drug Quality With Rollout Of New GMP Guidelines

Article reprinted from "PharmAsia News"- October 15, 2010

SHANGHAI - China's State FDA recently issued a note to provincial FDA offices to require pharma companies and active pharmaceutical ingredient producers to file a Common Technical Document when they submit manufacturing applications as an effort to improve drug quality and research and development work in China.

Opposition Party Lawmaker Criticizes Korean Government's Retreat From Funding Vaccinations

Article reprinted from "PharmAsia News"- October 12, 2010

SEOUL - A minor opposition party lawmaker accused the Korean government of backing down from its earlier stance to help fund compulsory vaccinations for diseases such as hepatitis B.